JP2023500685A5 - - Google Patents

Info

Publication number
JP2023500685A5
JP2023500685A5 JP2022525779A JP2022525779A JP2023500685A5 JP 2023500685 A5 JP2023500685 A5 JP 2023500685A5 JP 2022525779 A JP2022525779 A JP 2022525779A JP 2022525779 A JP2022525779 A JP 2022525779A JP 2023500685 A5 JP2023500685 A5 JP 2023500685A5
Authority
JP
Japan
Prior art keywords
alkoxy
alkyl
hydrogen
pharmaceutical product
product according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022525779A
Other languages
English (en)
Japanese (ja)
Other versions
JP7502811B2 (ja
JP2023500685A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2020/000912 external-priority patent/WO2021090061A1/en
Publication of JP2023500685A publication Critical patent/JP2023500685A/ja
Publication of JP2023500685A5 publication Critical patent/JP2023500685A5/ja
Application granted granted Critical
Publication of JP7502811B2 publication Critical patent/JP7502811B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022525779A 2019-11-05 2020-11-04 Betブロモドメイン阻害物質およびナトリウム依存性グルコース輸送体2阻害物質の組み合わせで主要な心血管有害事象(mace)を処置および/または予防する方法 Active JP7502811B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962930860P 2019-11-05 2019-11-05
US62/930,860 2019-11-05
PCT/IB2020/000912 WO2021090061A1 (en) 2019-11-05 2020-11-04 Methods of treatment and/or prevention of major adverse cardiovascular events (mace) with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor

Publications (3)

Publication Number Publication Date
JP2023500685A JP2023500685A (ja) 2023-01-10
JP2023500685A5 true JP2023500685A5 (cg-RX-API-DMAC10.html) 2023-11-13
JP7502811B2 JP7502811B2 (ja) 2024-06-19

Family

ID=75849803

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022525779A Active JP7502811B2 (ja) 2019-11-05 2020-11-04 Betブロモドメイン阻害物質およびナトリウム依存性グルコース輸送体2阻害物質の組み合わせで主要な心血管有害事象(mace)を処置および/または予防する方法

Country Status (18)

Country Link
US (1) US12551484B2 (cg-RX-API-DMAC10.html)
EP (1) EP4054584B1 (cg-RX-API-DMAC10.html)
JP (1) JP7502811B2 (cg-RX-API-DMAC10.html)
KR (1) KR102935008B1 (cg-RX-API-DMAC10.html)
CN (1) CN114650824A (cg-RX-API-DMAC10.html)
AU (1) AU2020377539B2 (cg-RX-API-DMAC10.html)
BR (1) BR112022008223A2 (cg-RX-API-DMAC10.html)
CA (1) CA3160147A1 (cg-RX-API-DMAC10.html)
DK (1) DK4054584T3 (cg-RX-API-DMAC10.html)
ES (1) ES3042146T3 (cg-RX-API-DMAC10.html)
FI (1) FI4054584T3 (cg-RX-API-DMAC10.html)
HU (1) HUE073043T2 (cg-RX-API-DMAC10.html)
IL (1) IL292696B2 (cg-RX-API-DMAC10.html)
MX (1) MX2022005029A (cg-RX-API-DMAC10.html)
PL (1) PL4054584T3 (cg-RX-API-DMAC10.html)
PT (1) PT4054584T (cg-RX-API-DMAC10.html)
TW (1) TWI867086B (cg-RX-API-DMAC10.html)
WO (1) WO2021090061A1 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12551484B2 (en) 2019-11-05 2026-02-17 Resverlogix Corp. Methods of treatment and/or prevention of major adverse cardiovascular events (MACE) with a combination of a BET bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor
EP4236957A4 (en) * 2020-10-30 2024-08-07 Resverlogix Corp. METHODS OF LOWERING HBA1C LEVELS USING A COMBINATION OF A BET BROMODOMAIN INHIBITOR AND A SODIUM-DEPENDENT GLUCOSE TRANSPORT-2 INHIBITOR
AU2021368618B2 (en) 2020-10-30 2025-02-27 Resverlogix Corp. Methods for improving renal function with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor
WO2022155303A1 (en) * 2021-01-14 2022-07-21 Lexicon Pharmaceuticals, Inc. Sotagliflozin for treating or preventing cardiovascular diseases

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007016525A2 (en) 2005-07-29 2007-02-08 Resverlogix Corp. Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
PT2118074E (pt) 2007-02-01 2014-03-20 Resverlogix Corp Compostos para a prevenção e tratamento de doenças cardiovasculares
US8114995B2 (en) 2008-06-26 2012-02-14 Resverlogix Corp. Methods of preparing quinazolinone derivatives
NZ617779A (en) 2009-03-18 2015-08-28 Resverlogix Corp Novel anti-inflammatory agents
KR20110135411A (ko) 2009-03-27 2011-12-16 브리스톨-마이어스 스큅 컴퍼니 Dpp-iv 억제제로 주요 유해 심장혈관 이벤트를 예방하는 방법
US9757368B2 (en) 2009-04-22 2017-09-12 Resverlogix Corp. Anti-inflammatory agents
CN106075451A (zh) 2009-05-27 2016-11-09 阿斯利康(瑞典)有限公司 使用sglt2抑制剂及其组合物在对先前用其它抗糖尿病药进行的治疗具有耐受的患者中治疗ii型糖尿病的方法
PT2773354T (pt) 2011-11-01 2019-07-17 Resverlogix Corp Formulações orais de libertação imediata para quinazolinonas substituídas
US20130281398A1 (en) 2012-04-19 2013-10-24 Rvx Therapeutics Inc. Treatment of diseases by epigenetic regulation
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
PL2986304T3 (pl) 2013-04-18 2022-05-02 Boehringer Ingelheim International Gmbh Kompozycja farmaceutyczna, sposoby leczenia i jej zastosowania
BR112016003584A8 (pt) 2013-08-21 2018-01-30 Resverlogix Corp composições farmaceuticas e uso das mesmas para regressão de placa acelerada
KR20160043118A (ko) 2013-08-21 2016-04-20 리스버로직스 코퍼레이션 가속화된 경화반 퇴행을 위한 조성물 및 치료방법
AR099936A1 (es) * 2014-04-04 2016-08-31 Sanofi Sa Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados
CN114984016A (zh) 2015-03-13 2022-09-02 雷斯韦洛吉克斯公司 用于治疗补体相关疾病之组合物及治疗方法
MA43037A (fr) * 2015-10-02 2018-08-08 Dana Farber Cancer Inst Inc Polythérapie par inhibiteurs de bromodomaine et blocage de point de contrôle
JP6849804B2 (ja) 2016-12-09 2021-03-31 クリスタル ファーマシューティカル(スーチョウ)カンパニー,リミテッド ブロモドメインタンパク質阻害薬の結晶形及びその製造方法並びに用途
US11419883B2 (en) 2017-05-05 2022-08-23 The Regents Of The University Of California Inhibiting senescent processes in beta cells for the prevention of type 1 diabetes
US12551484B2 (en) 2019-11-05 2026-02-17 Resverlogix Corp. Methods of treatment and/or prevention of major adverse cardiovascular events (MACE) with a combination of a BET bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor
KR20220124736A (ko) 2020-01-08 2022-09-14 리스버로직스 코퍼레이션 Bet 브로모도메인 억제제 및 디펩티딜 펩티다아제 4 억제제의 조합을 이용해 주요 심혈관 이상 반응(mace)을 치료 및/또는 예방하는 방법
AU2021368618B2 (en) 2020-10-30 2025-02-27 Resverlogix Corp. Methods for improving renal function with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor
EP4236957A4 (en) 2020-10-30 2024-08-07 Resverlogix Corp. METHODS OF LOWERING HBA1C LEVELS USING A COMBINATION OF A BET BROMODOMAIN INHIBITOR AND A SODIUM-DEPENDENT GLUCOSE TRANSPORT-2 INHIBITOR

Similar Documents

Publication Publication Date Title
US11026900B2 (en) Treatment or prevention of cardiovascular events via the administration of a colchicine derivative
US6432950B1 (en) Method for inhibiting neoplastic cells and related conditions by exposure to benzothienopyrimidine derivatives
AU2020234929B2 (en) Formulations of a compound and uses thereof
US9814724B2 (en) Antitumor effect potentiator and antitumor agent
RU2005102110A (ru) Способ и лекарственное средство для лечения тяжелой сердечной недостаточности
IL292696A (en) Methods for the treatment and/or prevention of severe harmful cardiovascular events with a combination of a bromodomain bet inhibitor and a sodium-dependent glucose transporter 2 inhibitor
CN101107001A (zh) 配合有α,α,α-三氟胸苷和胸苷磷酸化酶抑制剂的抗癌剂
JP2023509186A5 (cg-RX-API-DMAC10.html)
JP2023547475A5 (cg-RX-API-DMAC10.html)
WO2020045461A1 (ja) ピラゾロ[3,4-d]ピリミジン化合物を有効成分とする治療剤
MXPA06014477A (es) Agente antitumor, fortificador de efecto antitumor y metodo de terapia para cancer.
JP5409613B2 (ja) 抗腫瘍剤、キット及び癌治療方法
JP3450399B2 (ja) 血管新生阻害剤
JP2023549703A5 (cg-RX-API-DMAC10.html)
JPS6231689B2 (cg-RX-API-DMAC10.html)
HK1127546A (en) Antitumor effect potentiator and antitumor agent
KR20070026443A (ko) 허혈성 순환기 질환의 예방 및/또는 치료를 위한 약제